BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10561307)

  • 21. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
    Paff MT; Baccanari DP; Davis ST; Cao S; Tansik RL; Rustum YM; Spector T
    Invest New Drugs; 2000 Nov; 18(4):365-71. PubMed ID: 11081572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
    Sadahiro S; Suzuki T; Maeda Y; Ishikawa K; Tanaka Y; Yasuda S; Kamijo A; Makuuchi H; Murayama C
    Chemotherapy; 2007; 53(6):442-5. PubMed ID: 17952005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors.
    Levin J; Hohneker J
    Invest New Drugs; 2000 Nov; 18(4):383-90. PubMed ID: 11081574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
    Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
    Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
    Czito BG; Hong TJ; Cohen DP; Tyler DS; Lee CG; Anscher MS; Ludwig KA; Seigler HF; Mantyh C; Morse MA; Lockhart AC; Petros WP; Honeycutt W; Spector NL; Ertel PJ; Mangum SG; Hurwitz HI
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):779-85. PubMed ID: 14967434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
    Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
    Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
    Mauritz R; van Groeningen CJ; Smid K; Jansen G; Pinedo HM; Peters GJ
    Int J Cancer; 2007 Jun; 120(12):2609-12. PubMed ID: 17330233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
    Tsuji T; Sawai T; Takeshita H; Nakagoe T; Hidaka S; Yamaguchi H; Yasutake T; Nagayasu T; Tagawa Y
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):531-6. PubMed ID: 15309506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
    O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
    Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F
    Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster.
    Yan J; Tyring SK; McCrary MM; Lee PC; Haworth S; Raymond R; Olsen SJ; Diasio RB
    Clin Pharmacol Ther; 1997 May; 61(5):563-73. PubMed ID: 9164418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
    Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
    Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
    Endo M; Miwa M; Eda H; Ura M; Tanimura H; Ishikawa T; Miyazaki-Nose T; Hattori K; Shimma N; Yamada-Okabe H; Ishitsuka H
    Int J Cancer; 2003 Sep; 106(5):799-805. PubMed ID: 12866042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.
    van Staveren MC; van Kuilenburg AB; Guchelaar HJ; Meijer J; Punt CJ; de Jong RS; Gelderblom H; Maring JG
    Br J Clin Pharmacol; 2016 Mar; 81(3):553-61. PubMed ID: 26551538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
    Czito BG; Hong TJ; Cohen DP; Petros WP; Tyler DS; Pappas TN; Yu D; Lee CG; Lockhart AC; Morse MA; Fernando N; Hurwitz HI
    Cancer Invest; 2006 Feb; 24(1):9-17. PubMed ID: 16466986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
    Ishida H; Ohsawa T; Nakada H; Yokoyama M; Inokuma S; Shirakawa K; Yamada H; Hashimoto D
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):883-7. PubMed ID: 15222105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer.
    Shirota Y; Ichikawa W; Uetake H; Yamada H; Nihei Z; Sugihara K
    Ann Surg Oncol; 2002 Jul; 9(6):599-603. PubMed ID: 12095978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Salonga D; Danenberg KD; Johnson M; Metzger R; Groshen S; Tsao-Wei DD; Lenz HJ; Leichman CG; Leichman L; Diasio RB; Danenberg PV
    Clin Cancer Res; 2000 Apr; 6(4):1322-7. PubMed ID: 10778957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.
    McLeod HL; Sludden J; Murray GI; Keenan RA; Davidson AI; Park K; Koruth M; Cassidy J
    Br J Cancer; 1998; 77(3):461-5. PubMed ID: 9472644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo.
    Spector T; Harrington JA; Porter DJ
    Biochem Pharmacol; 1993 Dec; 46(12):2243-8. PubMed ID: 8274158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.